Skip to main content

Viking Therapeutics, Inc.

VKTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001607678

In the last 90 days, Viking Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 437 institutions reported holding it in 13F filings for Q2 2026, worth $2.96B in total; no superinvestor holds it.

13F holders, Q4 2024

Institutional positions in Viking Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
409
−5 vs. Q3 2024
Shares held
82.0M
−1.11M (−1.3%) vs. Q3 2024
Total value
$3.30B
−$1.92B (−36.7%) vs. Q3 2024
New holders
83
148 more added
Sold out
88
126 more reduced

8 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting VKTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2024: 409 institutions
Q1 2021: 144 institutionsQ2 2021: 138 institutionsQ3 2021: 135 institutionsQ4 2021: 140 institutionsQ1 2022: 140 institutionsQ2 2022: 115 institutionsQ3 2022: 107 institutionsQ4 2022: 129 institutionsQ1 2023: 185 institutionsQ2 2023: 193 institutionsQ3 2023: 179 institutionsQ4 2023: 197 institutionsQ1 2024: 373 institutionsQ2 2024: 388 institutionsQ3 2024: 422 institutionsQ4 2024: 409 institutionsQ1 2025: 373 institutionsQ2 2025: 392 institutionsQ3 2025: 371 institutionsQ4 2025: 427 institutionsQ1 2026: 414 institutionsQ2 2026: 437 institutions
Value heldQ4 2024: $3.30B
Q1 2021: $259.3MQ2 2021: $226.9MQ3 2021: $237.7MQ4 2021: $166.5MQ1 2022: $93.8MQ2 2022: $77.2MQ3 2022: $72.4MQ4 2022: $319.7MQ1 2023: $1.11BQ2 2023: $1.21BQ3 2023: $854.0MQ4 2023: $1.42BQ1 2024: $6.56BQ2 2024: $4.26BQ3 2024: $5.27BQ4 2024: $3.30BQ1 2025: $1.88BQ2 2025: $2.02BQ3 2025: $1.87BQ4 2025: $2.54BQ1 2026: $2.43BQ2 2026: $2.96B
Institutions holding VKTX and their total value by quarter
QuarterHoldersValue
Q2 2026437$2.96B
Q1 2026414$2.43B
Q4 2025427$2.54B
Q3 2025371$1.87B
Q2 2025392$2.02B
Q1 2025373$1.88B
Q4 2024409$3.30B
Q3 2024422$5.27B
Q2 2024388$4.26B
Q1 2024373$6.56B
Q4 2023197$1.42B
Q3 2023179$854.0M
Q2 2023193$1.21B
Q1 2023185$1.11B
Q4 2022129$319.7M
Q3 2022107$72.4M
Q2 2022115$77.2M
Q1 2022140$93.8M
Q4 2021140$166.5M
Q3 2021135$237.7M
Q2 2021138$226.9M
Q1 2021144$259.3M

Institutions, Q4 2024

Shares, value and share of portfolio for each institution holding Viking Therapeutics, Inc.; share changes are against Q3 2024.

Institutions holding VKTX in Q4 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Chartwell Investment Partners, LLC––––Not filed
ClariVest Asset Management LLC––––Not filed
9258 Wealth Management, LLC––––Not filed
Raymond James Trust N.A.––––Not filed
Planning Capital Management Corp––––Not filed